Association of MammaPrint index and 3-year outcome of patients with HR+HER2-early-stage breast cancer treated with chemotherapy with or without anthracycline

被引：0
|
作者：
O'Shaughnessy, Joyce
Graham, Cathy Lynne
Whitworth, Pat
Beitsch, Peter D.
Osborne, Cynthia R. C.
Rahman, Rakhshanda Layeequr
Brown, Eric Allen
Gold, Linsey P.
Johnson, Nathalie Mcdowell
Brufsky, Adam
Ramaswamy, Harshini
Stivers, Nicole
Menicucci, Andrea
Audeh, M. William
机构：
[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA
[2] Emory Univ, Atlanta, GA USA
[3] Nashville Breast Ctr, Nashville, TN USA
[4] Dallas Surg Grp, Dallas, TX USA
[5] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX USA
[6] Comprehens Breast Care, Troy, MI USA
[7] Legacy Hlth Syst, Portland, OR USA
[8] Univ Pittsburgh, Pittsburgh, PA USA
[9] Agendia Inc, Med Affairs, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
511
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predictive value of multigene assay for chemotherapy benefit in patients with HR+/HER2-early breast cancer
    Kwon, Mi Jeong
    CANCER RESEARCH, 2018, 78 (13)
  • [22] Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer
    Yao, Lu
    Zhang, Juan
    Liu, Yiqiang
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (06) : 553 - 561
  • [23] Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer
    Lu Yao
    Juan Zhang
    Yiqiang Liu
    Tao Ouyang
    Jinfeng Li
    Tianfeng Wang
    Zhaoqing Fan
    Tie Fan
    Benyao Lin
    Yuntao Xie
    Chinese Journal of Cancer Research, 2015, 27 (06) : 553 - 561
  • [24] PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
    Jensen, J. D.
    Knoop, A.
    Laenkholm, A. V.
    Grauslund, M.
    Jensen, M. B.
    Santoni-Rugiu, E.
    Andersson, M.
    Ewertz, M.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 2034 - 2042
  • [25] PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
    Jensen, J. D.
    Knoop, A.
    Laenkholm, A-, V
    Grauslund, M.
    Jensen, M-B
    Santoni-Rugiu, E.
    Andersson, M.
    Ewertz, M.
    APMIS, 2012, 120 : 16 - 16
  • [26] Outcome of adjuvant chemotherapy in elderly patients with early-stage, hormone receptor-positive, HER-2-negative breast cancer
    Ma, Sung Jun
    Oladeru, Oluwadamilola T.
    Singh, Anurag K.
    BREAST JOURNAL, 2020, 26 (10): : 2026 - 2030
  • [27] Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era
    Palmieri, Carlo
    Shah, Deep
    Krell, Jonathan
    Gojis, Ondrej
    Hogben, Katy
    Riddle, Pippa
    Ahmad, Riz
    Tat, Tri
    Fox, Kevin
    Porter, Andrew
    Mahmoud, Sarah
    Kirschke, Stephanie
    Shousha, Sami
    Gudi, Mihir
    Coombes, R. Charles
    Leonard, Robert
    Cleator, Susan
    CLINICAL BREAST CANCER, 2011, 11 (02) : 93 - 102
  • [28] Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy
    Liu, Wenjuan
    Zhang, Lingyun
    Shi, Jing
    Liu, Yunpeng
    Zhou, Lizhong
    Hou, Kezuo
    Qu, Xiujuan
    Teng, Yuee
    ONCOLOGY LETTERS, 2015, 9 (04) : 1707 - 1714
  • [29] 21-Gene Recurrence Score Index (ONCOTYPE DX) as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2-breast cancer
    Cudos, Ariadna Gasol
    Murillo, Serafin Morales
    Der-Abrain, Noemi Tuset
    Villellas, Felip Vilardell
    Cid, Laura Arbones
    Olive, Jordi Mele
    Morales, Carles Canosa
    CANCER RESEARCH, 2024, 84 (09)
  • [30] Response to "Late relapse rates in patients with early-stage hormone receptor positive and HER2+breast cancer treated with adjuvant chemotherapy and neoadjuvant chemotherapy"
    Burkbauer, Laura
    Goldbach, Macy
    Pomponio, Maria
    Tchou, Julia
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (06) : 1043 - 1043
12345